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Abstract
Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased
risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodu-
latory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccin-
ation coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine
safety and efficacy in IMID patients treated with immunosuppressive or immunomodulatory drugs and for-
mulates best-practice recommendations on vaccination in this population. Especially in the current era of
biological therapies, including TNF-blocking agents, special consideration should be given to vaccination
strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase
clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocomprom-
ized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune
response in patients under immunotherapy may have a negative impact on vaccination efficacy in this popu-
lation, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B,
influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of
immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit
an optimal immune response in immunocompetent individuals.
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Introduction
The term immune-mediated inflammatory disease (IMID)
covers a group of apparently unrelated diseases affect-
ing various organs and systems, such as RA, IBD and
psoriasis. However, these disorders share some
common genetic predispositions and inflammatory path-
ways, characterized by cytokine dysregulation. Hence,
similar anti-inflammatory treatment strategies, including
administration of immunosuppressive or immunomodula-
tory agents (hereafter named immunotherapy), are used to
treat these disorders [1].
Vaccination is a proven and well-established strategy
for prevention of infectious diseases in the general popu-
lation and in patients with IMID, who have an increased
risk of complications for some vaccine-preventable infec-
tions, due to both the nature of the disease and its immu-
nomodulatory treatment. In this article, we aim (i) to
summarize current scientific evidence about infection
risk, vaccine safety and efficacy in patients with IMID
and treatment-induced impaired immune competence
and (ii) to provide clinicians with a conceptual frame-
work and best practice recommendations on vaccine-
preventable diseases in this patient population.
Literature search and selection
The Medline database was searched through PubMed,
using the following key words, individually and in combin-
ation: ‘rheumatic disease’, ‘psoriasis’, ‘inflammatory
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Wbowel disease’, ‘vaccine safety’, ‘vaccine efficacy’, ‘im-
munization’, ‘vaccination’, ‘autoimmunity’, ‘infection’ and
‘guidelines’. Additional searches included the key words
mentioned above in combination with the names of spe-
cific vaccines or drugs. Additionally, the European Centre
for Disease Prevention and Control, the Centers
for Disease control (CDC), the British Society of
Rheumatology (BSR) and the World Health Organization
(WHO) web sites and publications were consulted for
recent papers and recommendations regarding immuno-
compromized patients and immunization. The reference
lists of retrieved articles were handsearched for relevant
publications.
Levels of evidence. The recommendations made in this
article are graded (Levels A–D) according to the classifi-
cation scheme of Shekelle et al. [2], depending on the
level of evidence supporting the recommendation.
IMID patients are at increased risk of
vaccine-preventable disease
Infectious disease is the net result of exposure to a patho-
gen and the subsequent reaction of the host’s defence
mechanisms. Since the immune response in patients
with IMID may be subdued, due to immunological
changes intrinsic to immune-mediated diseases and
immunotherapy, IMID patients may be at increased risk
of infection [3].
IMID and the directly linked infection risk
A comprehensive population-based retrospective study
comparing RA patients with matched controls reported a
nearly doubled incidence of documented infections in RA
patients [4], although evidence allowing to distinguish be-
tween increased infection risk due to the disease and its
treatment is sparse. RA-associated changes in cellular
immunity may predispose RA patients to infection [5].
Early reports suggest that RA intrinsically entails an ele-
vated susceptibility to infection [4, 6]. Predictive factors
for serious infection episodes in RA patients include RA
severity indices, such as presence of RF, increased sedi-
mentation rate and extra-articular involvement, as well as
corticosteroid use and the presence of comorbidities [7].
The excess mortality described in RA is partly attributable
to infection, with reported standardized mortality rates
due to infection in RA patients ranging from 4.2 to 14.9 [8].
In SLE, infectious complications occur in 25–45% of
patients, and up to 50% of the mortality is attributed to
infection. The increased infection rate in SLE patients is at
least partly related to immunological defects such as
complement deficiencies [9, 10].
In IBD, infections are over-represented as a cause of
death [11, 12]. Whether infections are implicated in the
onset of the disease is still a matter of debate [13].
Nevertheless, decreased intestinal barrier function,
immune deficiencies (deficiency in the defensin system,
macrophage immunodeficiency [14]) and malnutrition
[15] may contribute to the higher susceptibility of IBD
patients to certain infections. Abdominal sepsis may
occur as a direct complication of the disease.
For psoriasis, one study suggests that psoriasis pa-
tients are at increased risk for pneumonia and systemic
viral infections [16], whereas increased post-operative
infection risk after orthopaedic surgery—as a surrogate
marker of immune competence—is controversial in psor-
iasis patients [17]. Increased susceptibility to infection in
psoriasis patients thus remains a matter of debate.
Effect of immunotherapy on the risk of infection
in IMID
Treatment of IMID patients with corticosteroids, immuno-
suppressive drugs and targeted biological therapies such
as TNF blockers are the most important factors leading to
immunosuppression. IMID patients treated with immuno-
therapy must be regarded as immunocompromized
individuals, although the extent to which immune compe-
tence is impaired depends on the type and dose of
medication used, as well as the duration of therapy.
Immunotherapy predominantly impairs cellular immunity,
leaving the humoral immune response more or less intact.
Experience in transplant medicine indicates that the risk of
infection under immunotherapy varies with the degree of
immunosuppression [18]. Unfortunately, up to now no
clinical or laboratory measurements allow accurate as-
sessment of the immune status in order to identify pa-
tients at increased risk of infectious complications.
Cytokine profiling techniques may hold a promise for the
future in this respect [19]. Table 1 gives an overview of the
different classes of drugs used for treating IMID patients
and their effect on the immune system.
The use of corticosteroids has long been known to in-
crease the risk of infection. The degree of immunosup-
pression caused by corticosteroid therapy increases
with the dose and duration of treatment. Treatment
>2 weeks with >20mg/day of prednisolone is commonly
considered to induce clinically significant immunosup-
pression [20], whereas a meta-analysis showed that
cumulative doses of <500mg or mean daily doses of
<10mg are not associated with increased incidence of
infectious complications and can be considered as not
immunosuppressive [21].
In RA patients, corticosteroids significantly increase the
risk of infection, with relative risks of 1.15 and 1.9 for mild
and serious infections, respectively. The combined use of
corticosteroids and conventional DMARDs yielded a
comparably increased infection risk, whereas non-
biological DMARD therapy alone was not associated
with increased risk of infection [7, 22], although some of
these compounds have well-known negative effects on
the immune system.
Lacaille et al. [22] reported no elevated risk of infection
under MTX, whereas a case–control study reported a
small increase of the risk for pneumonia [23]. In the
latter study, cyclophosphamide and corticosteroids
were associated with the highest infection risk, where-
as moderate risk was observed under AZA. HCQ,
1816 www.rheumatology.oxfordjournals.org
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infections [23].
Biologicals revolutionized the treatment of IMID, but the
altered immune response to which they thank their thera-
peutic effect also leads to an increased risk of infection
(reviewed in [24, 25]). In RA, TNF inhibitors are associated
with an increased risk of infection vs conventional
DMARDs [25]. A retrospective study of infection risk
under anti-TNF therapy in clinical practice revealed infec-
tion rates [increasing from 3.4 (38.7) per 100 patient-years
before to 10.5 (86.9) during anti-TNF-therapy] well above
those reported in the registration trials for those products
[26]. The limited data available on abatacept and rituxi-
mab suggest that the risk of infections and serious infec-
tions with these products may be more limited or similar to
that of the TNF inhibitors [25]. A study comparing abata-
cept or infliximab with placebo suggested a more favour-
able safety profile of abatacept, with fewer serious
infections in the abatacept group [27]. In Crohn’s disease,
both registries and clinical practice in large referral centres
have only shown a slight increase of severe infection
under immunotherapy [28–30]. Infections seem to be
mostly attributed to steroids; combination of immunomo-
dulatory treatments increases significantly the risk for in-
fection [31, 32].
Vaccination strategy in patients
with IMID
IMID patients, in particular those under immunotherapy,
are at an increased risk for complications of some
vaccine-preventable infections (Table 2). Hence, for this
patient population the benefits of implementing a suitable
vaccination protocol in daily clinical practice are potential-
ly even greater than for the general population. When vac-
cination coverage in the population is high, herd immunity
grants a certain extent of protection to non-vaccinated
individuals by reducing the prevalence of the disease.
The infection risk in non-vaccinated individuals is not neg-
ligible; however, a recent study demonstrated that
non-vaccinated children in the USA have a 35 times
increased risk of contracting measles in comparison
with vaccinated children [33]. These findings stress the
important task that clinicians have to advocate
TABLE 1 Immunomodulatory drugs commonly used to treat IMID
Drug class Drug
Immunosuppressive
effect [20] Remarks
NSAIDs  
Corticosteroids + Immunosuppressive dose: >20mg/day of prednisone
or equivalent for >2 weeks [97]
Not immunosuppressive doses: <10mg/day or
cumulative doses <500mg [21]
DMARDs SSZ; 5-ASA   Immunomodulator in arthritis and IBD
Gold salts   Anti-inflammatory mechanism unclear [98]
HCQ   Blocks Toll-like receptor on dendritic cells
Cyclophosphamide + Alkylating agent
MTX + Anti-metabolite, folate antagonist, immunomodulator
LEF + Anti-proliferative agent, inhibits pyrimidine synthesis
AZA + Anti-proliferative agent, purine synthesis inhibitor
Ciclosporin + Calcineurin inhibitor, transplant-related
immunosuppressive drug
Anti-psoriatic drugs Acitretin   Second-generation retinoid
Fumarate   Anti-inflammatory and anti-proliferative action
Anti-TNF-a agents Infliximab + Chimaeric monoclonal anti-TNF antibody
Adalimumab + Human monoclonal anti-TNF antibody
Etanercept + TNF receptor–immunoglobin G fusion protein
Certolizumab + PEGylated Fab fragment of a humanized
anti-TNF monoclonal antibody
Golimumab + Human monoclonal anti-TNF antibody
Other biologicals Anakinra + IL-1 receptor antagonist, blocks IL-1 signalling
Rituximab + Anti-CD-20, reduces B-cell number
Abatacept + Anti-CTLA4, blocks T-cell co-stimulation
Tocilizumab + Anti-IL-6 receptor
Alefacept + LFA-3 immunoglobin G fusion protein, binds to CD2,
reduces T cells number
Efalizumab + Anti-CD-11, blocks leucocyte adhesion
and T-cell activation
Ustekinumab + Anti-p40 subunit of IL-12 and IL-23
5-ASA: 5-aminosalicylic acid; CD: cluster of differentiation; COX-2: cyclo-oxygenase-2; CTLA4: cytotoxic T-lymphocyte
antigen 4; LFA-3: lymphocyte function-associated antigen-3.
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Jean-Franc ¸ois Rahier et al.vaccination, especially for patients with increased risk of
infectious complications.
However, vaccination coverage of IMID patients is sur-
prisingly low. In RA patients, vaccination coverage rates
rarely exceed those in the general population [34]. A
survey in IBD patients revealed that only 45% of respond-
ents recalled tetanus immunization within the past
10 years, only 28% reported yearly influenza vaccination,
9% reported having received pneumococcal vaccine
and only approximately half the patients at risk were
vaccinated against hepatitis B [35].
Possible explanations for under-vaccination of IMID pa-
tients are unawareness of the increased infection risk, and
concerns about safety and efficacy of vaccination in this
patient group. Factors to consider when evaluating the
safety of a vaccine in IMID patients are the hypothetical
risk for a flare of the IMID after vaccination and, for live
vaccines, the risk of vaccine-induced infections. The re-
luctance of clinicians to vaccinate IMID patients may be
due to fear of vaccine-induced disease flares, and to the
concern whether the lower immune response observed in
IMID patients treated with immunomodulatory drugs still
provides sufficient protection against the disease.
Types of vaccines
Available vaccines can be categorized into inactivated or
inert vaccines vs live vaccines (Table 3). Live vaccines
have the advantage of providing good protection rates,
as they reproduce the natural infection, with active virus
replication and exposure of the vaccine to a large number
of immunogenic epitopes, thereby inducing a fast anti-
body response and good immunological memory.
Disadvantages of live vaccines include the risk for
transmission and persistence of the virus, risk for back-
mutation to a more virulent virus and more stringent
transport and storage requirements.
Inactivated vaccines have indisputable advantages in
terms of safety since they do not contain infectious
agents and are easier to transport and store. However,
they provide a less close imitation of natural infection
(no replication, no intracellular penetration and limited
number of epitopes in recombinant vaccines), and may
therefore need adjuvants and repeated exposure (boost-
ers) in order to induce an adequately protective immune
response.
Vaccine safety: impact on disease activity in IMID
patients
Part of clinicians’ concerns about the safety of vaccination
in IMID originated from a number of case reports suggest-
ing an impact of vaccination on IMID disease onset or
course [36, 37]. These publications led to a belief among
some clinicians that vaccination might trigger a flare of the
underlying IMID. Despite substantial research, a direct
and causal relationship between vaccination and flare of
disease has not been detected [36, 38, 40–59]. Live vac-
cines are generally contraindicated in immunocomprom-
ized individuals, so reports dealing with their effect on
disease activity are rare. In a relatively small retrospective
study, measles–mumps–rubella (MMR) booster vaccin-
ation in children with juvenile idiopathic arthritis (JIA) ap-
peared safe, as vaccination did not induce infection, nor
did it significantly increase disease activity or medication
use [39, 40].
For non-live vaccines, substantial literature data (sum-
marized in Table 4) supports the conclusion that
TABLE 3 Types of vaccines
Type of vaccine Example Description
Inactivated or inert vaccines
Chemically or thermally
inactivated
Salk poliomyelitis vaccine Chemical inactivation with formaldehyde or
b-propriolactone; physical inactivation by exposure to
high temperature or UV irradiation
Split virion or subunit vaccine Most influenza vaccines Contains only part of the virion
Recombinant vaccine Hepatitis B Virus proteins produced with recombinant DNA technique
Virus-like particle vaccine Human papillomavirus Consists of virus proteins without nucleic acid assembled
into a virion-like particle
Live vaccines
Related non-human virus Vaccinia
Bovine rotavirus W3
Attenuated virus Measles Attenuation is achieved by passaging in non-natural host
cells or when the vaccine administration route is different
from that of the natural infection
Mumps
Rubella
Yellow fever
Oral poliomyelitis
Varicella zoster vaccine
Temperature-sensitive
mutant
Flumist influenza virus This virus strain replicates at 25 C (intranasal administra-
tion) but not at 37 C (in the lungs)
Non-exhaustive table, illustrating the different vaccine types with one or more examples.
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laboratory parameters of disease activity. Most of this evi-
dence comes from medium-sized controlled trials in
which disease activity was mostly assessed by general
clinical symptoms and pain scores. Some studies add-
itionally used standardized clinical disease activity
scores such as DAS or SLEDAI. Laboratory measure-
ments minimally included sedimentation rate or CRP in
some studies supplemented with more specialized
disease activity markers. This evidence indicates that
inactivated vaccines for hepatitis B, influenza and
pneumococcal disease can be administered safely to
IMID patients (evidence Level B, except for hepatitis B
vaccination in SLE: Level C, influenza vaccination in RA:
Level A).
Vaccine safety: induction of IMID
A particular concern that certainly contributes to the reti-
cence of clinicians to actively promote vaccination in IMID
patients are the reports of a temporal association between
vaccination and new onset of autoimmune disease [41],
suggesting that vaccination acts as a potential trigger of
autoimmune disease.
In this context, it is important to distinguish autoimmun-
ity, which is an abnormal immune response directed
against host antigens, involving production of autoantibo-
dies or the presence of autoreactive T cells, without clear
symptoms of disease nor evolution towards an IMID, from
autoimmune disease itself [41]. Autoimmunity results from
complex interactions between genetic traits and environ-
mental factors and can be triggered by a number of sti-
muli, including local inflammation as well as viral, bacterial
and parasitic infections [42]. Vaccination could trigger
autoimmunity through the same mechanisms as natural
infection.
In 1976, a number of cases of Guillain–Barre ´ syndrome
occurred after swine flu vaccination [43]. This phenom-
enon was not repeated in subsequent influenza virus
campaigns [44]. The risk for Guillain–Barre ´ syndrome
after influenza vaccination is now estimated to be lower
than the risk resulting from severe influenza, and is not to
be considered as an argument against influenza vaccin-
ation [45]. In the 1990s, extensive epidemiological
research in France, where 25 million people (40% of the
population) received hepatitis B vaccination in this period,
did not observe an association between hepatitis B vac-
cination and multiple sclerosis [46] as suggested by earlier
case reports [38, 41, 47].
The incidence of idiopathic thrombocytopenia following
MMR vaccination is 1/30 000 in vaccinated children.
However, the risk of developing thrombocytopenia
after natural measles and rubella infection amounts to
1/3000 and 1/6000, respectively [48].
Incidence of joint symptoms after MMR vaccination is
slightly increased, but still lower than that after natural
rubella infection [49]. A transient increase in RF levels or
arthritis symptoms has been reported after immunization
against a number of agents (MMR, tetanus, paratyphoid,
mumps, diphtheria, polio, smallpox and hepatitis B), but
the incidence of RA among the vaccinated population was
similar to non-vaccinated controls [50]. After extensive
review of available studies, French pharmacovigilance
[51] and the WHO advisory committee on Vaccine
Safety [52] concluded that there is no convincing evidence
of causal relationship between hepatitis B vaccination and
a number of reported RA cases [37, 53–55].
In IBD, the observation that measles virus can persist in
intestinal tissue [56], in combination with the epidemio-
logical association of in utero [57] or perinatal [58] measles
infection with subsequent Crohn’s disease, led to the re-
fractory ‘measles hypothesis’ of Crohn’s disease. The ele-
vated risk for development of IBD in subjects vaccinated
against measles in a controversial study by Thompson
et al. [59] was not confirmed in subsequent studies [60–
62]. Available evidence does not support an association
between measles-containing vaccines and risk of IBD
[63]. A potential association between Bacille Calmette–
Gue ´rin (BCG) vaccination and Crohn’s disease still
needs further investigation [64, 65].
Extremely rare cases of psoriasis or psoriasis-like
esions have been reported following BCG vaccination
[66], and a case–control study reported rubella vaccin-
ation as a risk factor for PsA [67]. However, these data
must also be seen in relationship with the well-known
Ko ¨bner phenomenon that occurs in psoriasis, i.e. the de-
velopment of new plaques at sites of skin injury. In this
TABLE 4 Effect of vaccination (non-live vaccines) on IMID disease activity
Vaccine
Disease
activity RA JIA SLE IBD
Hepatitis B = Clin, Lab (CCT) [74] Clin (CCT) [101] Clin, Lab (UCT) [75]
Pneumococcal
vaccine
= Clin, Lab (CCT) [77] Clin, Lab (CCT) [77]
Clin, Lab (UCT) [102]
Influenza = Clin, Lab (RCT) [103]
Clin, Lab (CCT) [84, 86, 88, 93]
Clin, Lab (CCT) [86]
Clin (UCT) [87]
Clin (CCT) [89]
Summary of literature data on the effect of vaccination on IMID disease activity. ‘=’ indicates no significant effect. Non-live
vaccines are well-tolerated in IMID patients and do not increase either clinical (Clin) or laboratory (Lab) markers of disease
activity. Study design is recorded in parentheses: CCT: controlled clinical trial; UCT: uncontrolled clinical trial; RCT: rando-
mized controlled trial.
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tion of psoriatic skin lesions [67].
Vaccine safety: infection with live vaccines
The main safety issue in vaccination of IMID patients con-
cerns the use of live vaccines: like in other groups of im-
munocompromized individuals, the use of live vaccines is
contraindicated in IMID patients treated with immunomo-
dulatory drugs [68]. Immunocompromized individuals are
not capable to mount an adequate immune response to-
wards the vaccine virus and have an increased risk of
enhanced virus replication, possibly leading to persist-
ence of the virus or even to overt vaccine-associated dis-
ease. Caution should also be exerted when vaccinating
household contacts of IMID patients with live vaccines,
since virus replication after vaccination is often accompa-
nied by shedding of the virus, with possible subsequent
infection of patients. Transmission of vaccine virus to
household contacts increases disease protection cover-
age beyond vaccination coverage in the general popula-
tion, but for severely immunocompromized individuals this
may pose a risk of developing infectious disease with the
vaccine virus. Spreading of the vaccine virus to household
contacts has been described after oral poliomyelitis vac-
cination [69], which is therefore contraindicated for house-
hold contacts of IMID patients [68], and after rotavirus
vaccination [70]. MMR, varicella, zoster and BCG vaccin-
ation are not contraindicated for household contacts of
IMID patients [68].
Vaccine efficacy in IMID patients
Vaccine efficacy is defined as percentual risk reduction for
clinically significant infection in a vaccinated group vs a
control group [71]. Efficacy of a vaccine is prefer-
ably demonstrated through well-conducted and well-
controlled field efficacy trials, evaluating different possible
end points (infection, hospitalization and death) in different
settings and populations. However, field efficacy data are
not always available. In that case, demonstration of
B-cell-generated antibodies is often used as a surrogate
marker for vaccination-induced protection, because most
vaccines protect against infection or disease by inducing
a B-cell antibody response. In addition to seroconversion,
which indicates the presence of an antibody response, the
antibody titre as well as the quality of the antibody re-
sponse (in terms of binding avidity and bactericidal or
neutralizing activity of antibodies) are important as pre-
dictors of protection. Although antibody production ac-
counts for the largest part of the protective response,
cellular immune response is very important for immuno-
logical memory, and contributes substantially to the pro-
tection induced by some vaccines such as the influenza,
varicella zoster and BCG vaccines [72].
The reduced quality of the immune response in IMID
patients, especially in those under immunotherapy, may
thus have a negative effect on the efficacy of vaccination.
Reduced seroconversion rates after vaccination in IMID
patients may reduce the proportion of protected patients.
Diminished quantity or quality of the antibody response
may reduce the duration of protection provided by vac-
cination in individual patients, thus requiring shorter
vaccination intervals or additional boosters.
Table 5 summarizes the current evidence on antibody
response after vaccination in IMID patients for different
vaccines and treatment options. In a normal population,
a humoral immune response to hepatitis B vaccination is
expected in >90% of vaccines, whereas lower immune
response rates have been described in immunocomprom-
ized patients [73]. The percentage of RA and SLE patients
producing HBsAg antibodies after hepatitis B vaccination
was found to be in the normal range [74, 75]. Classical
DMARDs do not have a negative influence on the re-
sponse to hepatitis B vaccination (for RA and JIA: evi-
dence Level B), but etanercept and the combination of
etanercept and MTX significantly decrease response
rates to hepatitis B vaccination (for RA, evidence
Level B). The effect of the newer biologicals on the
immune response after hepatitis B vaccination remains
to be investigated.
For the polysaccharide pneumococcal vaccine, vaccine
response rates in RA and SLE patients were similar to
those in control populations. However, a subset of pa-
tients will remain unprotected after vaccination, since a
small percentage of patients responded to none or only
one of the seven polysaccharide antigens [76–78].
TNF-a inhibitors do not impair the response to pneumo-
coccal vaccination, but MTX decreases the response
rates to this vaccine [76, 77, 79]. A recent study by
Melmed et al. [80] shows a normal pneumococcal vaccin-
ation response in IBD patients without immunosuppres-
sive therapy and impaired vaccination responsiveness in
patients treated with TNF blockers in combination with
other immunomodulators (MTX, 6-mercaptopurine or
AZA). The B-cell targeting antibody rituximab in combin-
ation with MTX significantly reduced the percentage of
patients responding to pneumococcal vaccination with a
2-fold titre rise in comparison with patients treated with
MTX alone [81]. Efalizumab had no negative influence on
the responsiveness towards pneumococcal vaccination in
psoriasis patients [82], whereas abatacept caused im-
paired responsiveness in healthy controls [83].
Influenza vaccination of RA patients generates a good
humoral response [84], lower than [84] or comparable with
[85, 86] healthy controls. The response to influenza vac-
cination was not affected by the use of prednisone or
DMARDs [84]. Treatment with anti-TNF antibodies only
modestly decreases the antibody response to influenza
vaccination: anti-TNF treatment does not significantly
decrease the proportion of IMID patients reaching a
protective antibody titre after vaccination, but does
lower the post-vaccination geometric mean antibody
titres reached [85]. In SLE patients without prior vaccin-
ation, the percentage of seroconversions or 4-fold titre
rises after influenza vaccination was lower in comparison
with controls; vaccination response was not influenced by
treatment with immunosuppressive agents (AZA, HCQ,
prednisone) [87]. However, a seroconversion rate compar-
able with that in the control population was observed
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Jean-Franc ¸ois Rahier et al.when all SLE patients, including those with prior influenza
vaccination, were taken into account. This finding clearly
illustrates the importance of yearly repeated influenza vac-
cination [87]. Salemi et al. [88] recently reported year-to-
year progressive increase in immune response in RA
patients treated with TNF blockers.
Mamula et al. [89] observed a reduced seroconversion
rate and geometric mean titre after influenza vaccination
in IBD patients receiving immunotherapy (including bio-
logical therapy) compared with healthy controls, whereas
vaccine response rates in patients without immunother-
apy were similar to those in controls. A good seroconver-
sion rate was observed in another study evaluating
influenza vaccine in children with IBD [90]. Some studies
observed an impaired immune response after influenza
vaccination in patients treated with anti-TNF agents [89,
91], but all studies report a significant percentage of re-
sponders in anti-TNF-treated patients [85, 88, 91].
Rituximab significantly reduces seroconversion rates
after influenza vaccination of RA patients [92, 93], and
the immune responsiveness is only modestly restored
after 6–10 months [93]. The effect of abatacept and efali-
zumab on the responsiveness to influenza vaccination is
still unknown. Although the studies described here are
heterogeneous in design, evaluated parameters of vac-
cine responsiveness and control groups, they all conclude
that a considerable proportion of IMID patients are able to
respond to hepatitis B, pneumococcal and influenza vac-
cination, so as to warrant the administration of these
vaccines to IMID patients (evidence Level B).
Recommendations for vaccination of
IMID patients
Except for live vaccines, the risk:benefit ratio for vaccin-
ation of IMID patients with reduced immune competence
is favourable. For most vaccine-preventable diseases,
IMID patients are at comparable or elevated risk of infec-
tion, and vaccination is generally able to elicit a protective
humoral immune response in most patients (evidence
Level B), although the fraction of protected patients, as
well as the antibody titre and duration of protection may
be lower in IMID patients, especially those under immuno-
therapy, in comparison with the general population.
General recommendations
A detailed overview of vaccination recommendations for
IMID patients is given in Table 2. As in the general popu-
lation, the immunization status of patients with IMID
should be checked and vaccination considered for tet-
anus, diphtheria and pertussis (evidence Level B).
Influenza, pneumococcal and hepatitis B vaccines are
safe and generally sufficiently immunogenic in patients
with IMID (evidence Level B).
Live vaccines (MMR, oral poliomyelitis vaccine, yellow
fever and varicella zoster) are contraindicated in IMID pa-
tients under immunotherapy (evidence Level B). Although
the varicella zoster vaccine is a live vaccine and is as such
contraindicated in immunocompromized individuals,
some consider the risk:benefit ratio for this vaccine bene-
ficial for patients on low-dose immunotherapy [94], espe-
cially since rescue therapy with acyclovir is possible in
case of virus persistence or infectious symptoms after
varicella zoster vaccination [94].
Inactivated travel-related vaccines can be administered
safely to IMID patients, although protection against dis-
ease cannot always be guaranteed (evidence Level B).
Yellow fever vaccination is contraindicated in immuno-
compromized patients, since it is a live vaccine (evidence
Level B). Vaccination for patients on immunotherapy tra-
velling to countries or regions with increased infection
pressure or frequently travelling around the world should
be discussed with a specialist in travel medicine.
Timing of vaccination
Vaccination status is best checked and updated before
the start of immunotherapy: live vaccines are not contra-
indicated at that time and inactivated vaccines elicit an
optimal immune response in immunocompetent individ-
uals. In IBD, it has even been suggested to vaccinate at
the time of diagnosis, particularly in patients with risk fac-
tors for a rapid evolution towards severe disease requiring
immunosuppressive therapies [95]. Inactivated vaccines
can be administered safely to patients under immunother-
apy, but live vaccines must be given 3–4 weeks before
(re)start of therapy, to ensure that virus replication has
ended before impairing the patient’s immune competence
[68] (evidence Level D).
The duration of therapy discontinuation needed in order
to safely administer a live vaccine depends on the type,
dose and duration of the therapy. As a rule of thumb, a
period of 3 months is estimated for the immune status to
be completely restored (evidence Level D), except for cor-
ticosteroid therapy, where a waiting period of 1 month is
thought to be sufficient (evidence Level D).
Vaccination of household contacts
Close contacts of persons with altered immune compe-
tence can safely receive all age-appropriate vaccines (evi-
dence Level B), with the exception of live oral poliomyelitis
vaccine, which has been replaced by the injectable inac-
tivated vaccine in industrialized countries. MMR, varicella
and rotavirus vaccines should be administered when indi-
cated. MMR vaccine viruses are not transmitted to con-
tacts, and transmission of varicella vaccine is rare [68].
The risk of rotavirus transmission to immunocompromized
household contacts is estimated to be much lower than
the risk of contracting wild-type rotavirus infection [70].
However, to minimize potential rotavirus transmission,
hand hygiene measures after contact with faeces of
a rotavirus-vaccinated infant should last for at least
1 week [68, 96].
In summary, vaccination is a very valuable measure to
prevent increased morbidity and mortality from
vaccine-preventable disease in the IMID population that
is at increased risk for a number of vaccine-preventable
diseases. Vaccinations are best given to IMID patients
before introduction of immunotherapy, since live vaccines
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Vaccination and IMID(MMR, BCG and yellow fever) are generally contraindi-
cated during immunotherapy and vaccine response is op-
timal in immunocompetent individuals. Vaccination with
inactive vaccines can be given normally in these patients,
keeping in mind that—depending on the degree of im-
munosuppression—the response to the vaccine and po-
tentially the period of protection are more limited in these
patients. Vaccines for patients on immunotherapy travel-
ling to endemic countries or frequently travelling around
the world should be discussed with a travel medicine
specialist.
Rheumatology key messages
. Patients with immune-mediated inflammatory
disease are at increased risk for a number
of vaccine-preventable diseases.
. Inactive vaccines are considered safe and generally
effective in IMID patients.
. Live vaccines are contraindicated in IMID patients
under immunosuppressive therapy.
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